Invex Therapeutics (ASX:IXC) ROE % Adjusted to Book Value: -14.84% (As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
37 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics ROE % Adjusted to Book Value?

Invex Therapeutics ASX:IXC 37 ROE % Adjusted to Book Value is -14.84% as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's ROE % for the quarter that ended in Dec. 2025 was -29.24%. Invex Therapeutics's PB Ratio for the quarter that ended in Dec. 2025 was 1.97. Invex Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -14.84%.

Invex Therapeutics ROE % Adjusted to Book Value Related Terms

Invex Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics ROE % Adjusted to Book Value Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -5.47 -9.96 -43.92 -15.44 -6.87

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.47 21.71 -14.02 -3.56 -14.84

ASX:IXC vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Invex Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's ROE % Adjusted to Book Value falls into.


ASX:IXC
37GF Score
Invex Therapeutics Ltd ASX:IXC
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics ROE % Adjusted to Book Value Calculation

Invex Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.72% / 1.27
=-6.87%

Invex Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-29.24% / 1.97
=-14.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -14.84% mean?
Invex Therapeutics (ASX:IXC) has a ROE % Adjusted to Book Value of -14.84% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' ROE % Adjusted to Book Value too high?
Invex Therapeutics' current ROE % Adjusted to Book Value is -14.84%. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Invex Therapeutics' ROE % Adjusted to Book Value of -14.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current ROE % Adjusted to Book Value is -14.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current ROE % Adjusted to Book Value of -14.84%. The current ROE % Adjusted to Book Value is -14.84%. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current ROE % Adjusted to Book Value is -14.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score

Get the complete analysis for ASX:IXC

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price